Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction

Abstract

Background:

Endostatin is a circulating endogenous angiogenesis inhibitor preventing neovascularization. Previous studies demonstrated the prognostic value of Endostatin among patients with heart failure with reduced ejection fraction (HFrEF). However, the role of Endostatin among patients with heart failure with preserved ejection fraction (HFpEF) remains unclear.

Objective:

This study aimed to investigate the association between serum Endostatin levels, natriuretic peptide levels and the severity of left ventricular diastolic dysfunction and the diagnosis of HFpEF.

Methods:

Endostatin serum concentrations were measured in 301 patients comprising 77 HFpEF patients, 169 patients with asymptomatic left ventricular diastolic dysfunction (ALVDD), and 55 controls with normal cardiac function.

Results:

Endostatin serum levels were significantly elevated in patients with HFpEF (median/interquartile range 179.0 [159-220]) and ALVDD (163.8 [145.4-191.3]) compared to controls (149.1 [130.6-176.9]), p < 0.001 and p = 0.004, respectively) and significant correlated with N-terminal pro B-type natriuretic peptide (NT-proBNP).

Conclusions:

This hypothesis-generating pilot study gives first evidence that Endostatin correlates with the severity of diastolic dysfunction and may become a novel biomarker for HFpEF. We hypothesize a rise in Endostatin levels may reflect inhibition of adaptive angiogenesis and adverse cardiac remodeling.

Keywords:
Heart Failure; Endostatins; Natriuretic Peptides; Biomarkers; Stroke Volume

Resumo

Fundamentos:

A Endostatina é um inibidor circulante endógeno da angiogênese que previne a neovascularização. Estudos anteriores demonstraram o valor prognóstico da Endostatina em pacientes com insuficiência cardíaca com fracção de ejeção reduzida (ICFEr). No entanto, o papel da Endostatina entre os pacientes com insuficiência cardíaca com fração de ejeção preservada (ICFEp) permanece incerto.

Objetivo:

Investigar a associação entre os níveis séricos de Endostatina, níveis de peptídeos natriuréticos e a gravidade de disfunção ventricular esquerda e diastólica e o diagnóstico de ICFEp.

Métodos:

Mediu-se a concentração sérica de Endostatina em 301 pacientes, compreendendo 77 pacientes com ICFEp, 169 pacientes com disfunção ventricular esquerda assintomática diastólica (DVEAD) e 55 controles com a função cardíaca normal. Resultados: Os níveis de Endostatina no soro foram significativamente elevados em pacientes com ICFEp (mediana / intervalo interquartil 179,0 [159-220]) e DVEAD (163,8 [145,4-191,3]) em comparação com os controles (149,1 [130,6-176,9]), p < 0,001 e p = 0,004, respectivamente) e correlação significativa com o terminal do pro-peptídeo natriurético tipo B (NT-proBNP).

Conclusões:

Este estudo piloto gerador de hipótese fornece a primeira evidência de que a Endostatina se correlaciona com a gravidade da disfunção diastólica e pode tornar-se um novo biomarcador para ICFEp. Nossa hipótese é de que um aumento nos níveis de Endostatina pode refletir inibição da angiogênese adaptativa e remodelação cardíaca adversa.

Palavras-chave:
Insuficiência Cardíaca; Endostatinas; Peptídeos Natriuréticos; Biomarcadores; Volume Sistólico

Introduction

The patient population affected by heart failure (HF) is growing in a constant manner. This is because of an aging society, western lifestyle and improved acute clinical care (e.g. after myocardial infarction).¹ Although, the treatment of chronic conditions improved over the last decades, mortality and morbidity rates in this patient population are amongst the highest for western healthcare systems.² In the United States (US) HF is the leading cause for hospitalization for patients older > 65 years of age.³ In 2030 the direct costs for heart failure will reach 70 billion US$ in the US alone.⁴ Half of the patients affected by HF present with a diastolic dysfunction and a preserved ejection fraction (HFpEF), with this proportion increasing.⁵ Clinical data proves that those patients suffering from a reduced ejection fraction (HFrEF) show better outcomes compared to HFpEF patients.^6-8 A reason might be that no therapy has been shown to improve outcomes in HFpEF.⁹ Current therapeutic options including fluid management, blood pressure control and physical exerciseto relief patients' symptoms. A major drawback regarding the development of new therapies for HFpEF, is the absence of clear diagnostic criteria.¹⁰ This makes the definition of patient populations for clinical studies difficult. At present, the diagnosis is solely based echocardiography. Especially, the separation between HFpEF and HFrEF is even more challenging and misleading in patients with newly diagnosed HF.¹¹ Therefore new strategies for disease phenotyping in HF are urgently needed. New biomarkers may achieve better disease phenotyping.¹² Although, many reports have been published on HF biomarkers over the last decades, the impact on clinical decision making is still limited.¹³ BNP/NTproBNP demonstrated high clinical utility to identify patients at high risk for heart failure hospitalization and death. However, in this context these markers for clinical studies are only applicable in relatively stable patients and not in terminal HF patients. Furthermore, the use of BNP/NTproBNP in clinical practice to optimize therapy with drugs, which are known to improve patient`s outcome is suitable.¹⁴ However, BNP/NTproBNP is not accepted as surrogate endpoint and can only exploratorily be used as endpoint in clinical trials. The appraisal of clinical utility of BNP/NTproBNP manifests in the current guidelines for the management of heart failure.¹⁵ A number of publications propose Endostatin, a potent angiogenesis inhibitor, known mostly from oncology, as a potential new HF biomarker candidate.^16-18 Most importantly Gouya et al. reported in a prospective observational cohort study in 151 HF patients, a correlation between elevated circulating Endostatin levels and mortality. Furthermore, this study showed a clear association between Endostatin levels and progressing diastolic dysfunction, the key characteristic of HFpEF.¹⁹ This is why we hypothesize that Endostatin could potentially be a biomarker suitable to diagnose and disease phenotype HFpEF patients. In the present study, we aimed to investigate the sole role of Endostatin as a biomarker for HFpEF and diastolic dysfunction.

Methods

The study protocol was approved by the Ethics Committee of the Private University of Witten/Herdecke, Germany (project n°. 91/08) and conducted in accordance with the Declaration of Helsinki. Signed written informed consent was obtained from all patients.

Study population

Participants of the prospective observational cohort study were patients contacting the HELIOS Klinikum Wuppertal Heart Center (Wuppertal, Germany) for elective coronary angiography or diagnostic work-up of heart failure. Patients with a stable or suspected coronary artery disease (CAD) and/or a diagnostic workup of CHF were included in the study. The exclusion criteria were: left ventricular ejection fraction (EF) < 50%, known CAD with progressive chest pain within the last month, coronary angioplasty or myocardial infarction within 6 weeks, hypertrophic cardiomyopathy, moderate-to-severe valvular heart disease, uncontrolled hypertension, atrial fibrillation or other severe arrhythmias, serum-creatinine > 2,0 mg/dl. Patients selected for the control group had to have no history or symptoms of CHF, a normal ejection fraction > 55%, a ratio of the early diastolic transmitral velocity (E) and the early diastolic tissue Doppler velocity (E´) of < 8, and normal NTproBNP values. A total of 301 patients were recruited and assigned to three groups based on echocardiographic diagnostic criteria as recommended by the European Society of Cardiology.²⁰ The control group consisted of 55 patients (29 males) with normal diastolic function (DF). The group with asymptomatic left ventricular diastolic dysfunction (ALVDD) contained 169 patients (95 males) with E medial < 8 cm/s, E/E' medial ratio 8-15 and NT-proBNP levels < 220 pg/ml. The group with HFpEF comprised 77 patients (46 females, 31 males) displaying ALVDD Grad II - III with E/E´ratio > 15, NT-proBNP levels > 220 pg/mL and current or previous signs or symptoms of heart failure.

Echocardiography

Echocardiography was performed using a standard ultrasound system (Vivid 7, General Electric, Milwaukee, Wisconsin). A complete transthoracic study was performed including 2D, M-mode, spectral and colour Doppler techniques following current recommendations and guidelines.^21,22 The left atrium volume index (LAVI) was calculated using the biplane area-length method. Left ventricular EF was measured by means of the modified biplane Simpson's method.²³ Left ventricular mass index (LVMi) was computed with the Devereux formula indexed to the body surface.²² HFpEF was defined in accordance with the EAE/ASE recommendation, based on the assessment of left ventricular diastolic function.²⁴ Primary measurements included mitral inflow peak early (E-wave) and late (A-wave) diastolic filling velocities as well as systolic (S) and early diastolic (E') mitral annular velocities whereat in each case three consecutive beats were measured and averaged. Conventional transmitral flow was measured with Pulse-waved Doppler (PW). PW tissue Doppler imaging (DTI) was performed at the junction of the septal and lateral mitral annulus in the apical 4-chamber view. Based on primary measurements E/A and E/E' ratios were calculated.

Laboratory analysis

Peripheral venous whole blood samples were taken after 5 minutes at rest for routine laboratory testing (OGTT, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, creatine, leucocytes, hemoglobin, creatin kinase, TSH, hsCRP, GOT, GPT). Blood was drawn into pyrogen-free tubes without any additives, centrifuged at room temperature, aliquoted and stored at -80°C. All laboratory analysis were outsourced to Roche Diagnostics (Penzberg, Germany) and performed on blinded samples. For analysis of plasma NT-proBNP the Elecsys 2010 NT-proBNP assay (Roche Diagnostics, Mannheim, Germany) was used. For measurement of Endostatin the ELISA assay of R&D Systems (Minneapolis, MN USA) was used. All assays were performed according to manufacturer's recommendations.

Statistical analysis

All analyses were performed using SPSS statistical software (SPSS 19.0, Chicago, IL, USA). The data are presented as median with 25^th/75^th percentiles (interquartile range) for continuous variables or as absolute numbers and corresponding percentages for categorical variables unless otherwise specified. Log transformed values were used for analysis as appropriate. A p-value < 0.05 was considered statistically significant. We used the Kolmogorov-Smirnov test as appropriate to test for normal distribution. The Mann-Whitney U-test was used to analyze differences between the medians of two groups and the Kruskal-Wallis test to test the equality of medians among more than two distinct groups. Fisher's Test was used for the comparison of two sets of binary variables and the c² test to evaluate differences in proportions in more than 2 sets of categorical variables. Endostatin and NT-proBNP levels were compared across subjects with normal diastolic function, mild ALVDD and HFpEF by the Mann-Whitney U-test, and Jonckheere-Terpstra test. Spearman rank correlation was used to identify variables associated with Endostatin. A multivariable model was included to predict the presence of HFpEF and included the following covariates: Endostatin, age, gender, diabetes, hypertension, coronary artery disease and body mass index. Due to the exploratory nature of this study, there is no minimum required sample size.

Results

Study population characteristics

Table 1 provides an overview of the clinical characteristics of all 301 patients included in our study. The three groups showed comparable diastolic blood pressure, resting heart rate and history of myocardial infarction and stroke. Patients with mild ALVDD or HFpEF were older, more obese, had a higher systolic blood pressure on average and showed a higher prevalence of comorbidities including CAD and coronary artery bypass graft, as well as cardiovascular disease risk. In addition, treatments varied across groups.

Table 1
Baseline characteristics of the study population. Values are median (25 75interquartile range) or absolute numbers and percentage (%)

Clinical variables(median/interquartile range or %)	Studied patient groups			p value
	Control (n = 55)	mild ALVDD (n = 169)	HFpEF (n = 77)
Age (years)	54 (48-61)	66 (58-71)	73 (68-77)	< 0.001*
BMI (kg/m2)	25.5 (24.1-29.1)	27.8 (25.6-32.3)	27.5 (25.7-32.0)	0.001*
Waist circumference (cm)	98 (86-107)	102 (94-114)	102 (98-111)	0.002*
Hip circumference(cm)	98 (94-103)	103 (96-111)	105 (98-114)	0.003*
Systolic BP (mmHg)	125 (110-136)	134 (127-140)	136 (130-140)	0.001*
Diastolic BP (mmHg)	80 (70-80)	80 (76-84)	80 (72-84)	0.12
Resting HR (beats/min)	70 (68-76)	72 (69-76)	70 (65-76)	0.51
CAD, n (%)	21 (38,2)	99 (58,6)	49 (63,6)	0.009*
CABG, n (%)	1 (2.0)	5 (3.0)	9 (11.7)	0.007*
PCI, n (%)	15 (27.3)	75 (44.4)	33 (42.9)	0.074
History of MI, n (%)	8 (14.5)	36 (21.3)	17 (22.1)	0.501
History of stroke, n (%)	1 (2.0)	5 (3.0)	3 (3.9)	0.824
Cardiovascular risk factors
Treated hypertension, n (%)	38 (69.1)	148 (88.1)	73 (96.1)	< 0.001*
Diabetes mellitus, n (%)	4 (7.3)	45 (26.6)	22 (28,6)	< 0.001*
Medication
ACE inhibitor, n (%)	26 (47.3)	110 (65.1)	42 (54.5)	0.042*
AT1 receptor blocker, n (%)	6 (10.9)	17 (10.1)	23 (29.9)	< 0.001*
Diuretics, n (%)	8 (14.5)	45 (26.6)	36 (49.8)	< 0.001*
Ca2 blocker, n (%)	6 (10.9)	23 (13.6)	21 (27.3)	0.013*
Β-blocker, n (%)	28 (50.9)	103 (60.9)	57 (74.0)	0.021*

• ^*
  statistically significant (p < 0.05). BMI: body mass index; BP: blood pressure; HR: heart rate; CAD: coronary artery disease; CABG: coronary artery bypass graft; PCI: percutaneous coronary intervention; MI: myocardial infarction; DF: diastolic function; ALVDD: left ventricular diastolic dysfunction; HFpEF: heart failure with preserved ejection fraction; NS: non-significant. The Mann-Whitney U-test was used to analyze differences between the medians of two groups and the Kruskal-Wallis test to test the equality of medians among more than two distinct groups.

Endostatin and diastolic function

Table 2 summarizes the laboratory data and echocardiographic function parameter stratified by the study groups HFpEF vs. ALVDD vs. controls. Levels of Endostatin were 179.0 [159-220] ng/mL in HFpEF, 163.8 [145.4-191.3] ng/mL in ALVDD and 149 [130.6 - 176.9] ng/mL in the control group, respectively (Figure 1A). Serum levels of Endostatin were significantly higher in patients with HFpEF (p < 0.001) and mild ALVDD (p = 0.001; Table 2) compared to individuals from the control group. Furthermore, Endostatin serum concentration was elevated in patients with mild ALVDD compared to asymptomatic controls with normal diastolic and systolic function (p = 0,004). In addition, there was a significant association between increasing Endostatin quartiles and higher NT-pro-BNP levels. No clinically relevant differences were observed in the clinical routine laboratory assessments. In multivariable analysis included the covariates Endostatin, age, gender, diabetes, hypertension, coronary artery disease and body mass index, age (p < 0.001) and Endostatin (p = 0.008 were independently associated with HFpEF

Table 2
Laboratory data and echocardiographic parameters. (25-75interquartile range) or absolute numbers and percentage (%) X² test was used as appropriate

Clinical variables	Studied patient groups			p value
	Control (n = 55)	mild ALVDD (n = 169)	HFpEF (n = 77)
Biomarker
Endostatin (ng/ml)	149.1 (130.6-176.9)	163.8 (145.4-191.3)	179.0 (159-220)	< 0.001*
NT-pro-BNP (pg/ml)	90.1 (45.8-129.2)	86.7 (43.7-170.7)	343.6 (151.7-703.4)	< 0.001*
Routine parameter
Total cholesterol (mg/dl)	189 (163-228)	193 (171-221)	191 (170-210)	NS
LDL-cholesterol (mg/dl)	107 (89-135)	109 (89-135)	109 (86-129)	NS
HDL-cholesterol (mg/dl)	53 (46-64)	50 (38-62)	48 (41-61)	NS
Triclyceride (mg/dl)	119 (83-185)	142 (100-206)	131 (104-189)	NS
Lp (a) (mg/dl)	8 (5-27)	18 (6-39)	15 (6-52)	NS
TSH (mU/l)	1.20 (0.94-2.09)	1.42 (0.824-2.08)	1.315 (0.80-1.90)	NS
Creatinine (mg/dl)	0.8 (0.7-0.9)	0.9 (0.7-0.9)	0.9 (0.75-1.10)	NS
hsCRP	0.1 (0.1-0.3)	0.3 (0.1-0.6)	0.3 (0.2-0.69)	0.005*
Glucose	89 (84-97)	100 (91-111)	97 (89-103)	0.020*
Hb (mg/dl)	14.3 (13.3-15.1)	14.1 (13.2-15.0)	13.6 (12.5-14.5)	0.004*
CK (U/l)	76 (58-105)	78 (60-114)	72 (55-104)	NS
SGOT (U/l)	25 (21-31)	25 (21-31)	26 (21-32)	NS
LV geometry
IVS (mm)	10 (9-11)	12 (10-13)	12 (11-14)	< 0.001*
PLW (mm)	10 (9-11)	12 (10-13)	12 (11-14)	< 0.001*
LVEDD(mm)	44 (42-47)	44 (39-48)	45 (41-50)	NS
LVESD (mm)	30 (28-34)	29 (25-34)	31 (27-36)	NS
LVMi (g/m²)	72 (62-84)	81 (67-102)	91 (77-119)	< 0.001*
Systolic function
EF (%)	68 (62-72)	67 (61-71)	67 (63-73)	NS
Smax (cm/s)	7.2 (6.3-8.0)	6.3 (5.7-7.5)	6.1 (5.4-6.7)	< 0.001*
Diastolic function
LA-Index (ml/m2)	25.4 (21.8-28.7)	29.8 (25.7-33.3)	39.3 (36.7-49.1)	< 0.001*
E (cm/s)	60 (60-80)	60 (50-70)	80 (70-90)	< 0.001*
A (cm/s)	60 (50-70)	80 (70-90)	80 (70-90)	< 0.001*
E/A ratio	1.14 (0.68-1.25)	0.75 (0.67-0.86)	1.11 (0.85-1.25)	< 0.001*
E'septal (cm/s)	8.4 (7.3-9.4)	5.9 (5.2-6.8)	5.4 (4.6-6.3)	< 0.001*
E'lateral (cm/s)	10.7 (9.5-13.0)	8.2 (6.9-9.5)	6.9 (5.6-8.4)	< 0.001*
Average E'(cm/s)	9.8 (8.6-11.0)	7.2 (6.1-8.1)	6.2 (5.2-7.2)	< 0.001*
E/E'septal ratio	8.0 (6.9-9.0)	10.2 (8.3-11.9)	15.1 (12.5-17.1)	< 0.001*
E/E'average ratio	7.0 (6.0-7.7)	8.4 (6.8-10.1)	13.3 (11.1-14.8)	< 0.001*

• ^*
  statistically significant (p < 0.05); NT-proBNP: N-terminal fragment of the prohormone B-type natriuretic peptide; LDL: low density lipoprotein; HDL: high density lipoprotein; Lp (a): lipoprotein (a); TSH: thyroid stimulating hormone; hsCRP: high sensitive C-reactive protein; Hb: hemoglobin; CK: creatinkinase; SGOT: serum glutamic oxaloacetic transaminase; IVS: interventricular septum; PLW: posterior lateral wall; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; EF: ejection fraction; LA: left atrial; E: early diastolic transmitral velocity; A: late diastolic transmitral velocity; E': early diastolic tissue Doppler velocity; DF: diastolic function; LVDD: left ventricular diastolic dysfunction; HFpEF: heart failure with preserved ejection fraction; NS: non-significant. The Mann‑Whitney U-test was used to analyze differences between the medians of two groups and the Kruskal-Wallis test to test the equality of medians among more than two distinct groups.

Figure 1
(A) The boxplot graphics show serum Endostatin levels for the ALVDD, HFpEF patients and the control group. (B)The correlation between Endostatin levels and the E/E' ratio as surrogate for increased left ventricular filling pressures. (C) The logarithmic dot blot displays the correlation of Endostatin serum levels with NT-proBNP.

Association of Endostatin levels with cardiac structure and function

Increasing quartiles of Endostatin were significantly associated with structural changes of the heart like the extent of LV- hypertrophy and left atrial enlargement, reflecting adverse cardiac remodeling. Moreover, increasing quartiles of Endostatin were significantly associated with worsening diastolic function measured by tissue Doppler imaging (E', E/E') (table 3). Thus, patients within the highest quartiles of Endostatin serum levels showed more advanced cardiac remodeling (LV hypertrophy and left atrial enlargement) as well as more severe diastolic function abnormalities reflecting increasing left ventricular filling pressures (Figure 1B). Consistently, there was a significant positive moderate correlation between Endostatin and NT-proBNP levels (r = 0.32, p < 0.001; Figure 1C).

Table 3
Echocardiographic parameters stratified according to serum Endostatin quartiles. Values are median (interquartile range) or n (%). X² test was used as appropriate

Parameter	Endostatin 1rd quartile	Endostatin 2nd quartile	Endostatin 3rd quartile	Endostatin 4th quartile	p value
LV geometry
IVS (mm)	11 (9-12)	12 (11-13)	12 (11-13)	12 10-14)	0.032*
PLW (mm)	11 (10-13)	11 (10-13)	12 (10-13)	12 (10-14)	NS
LVEDD (mm)	44 (41-47)	43 (40-47)	47 (40-49)	45 (40-48)	NS
LEVSD (mm)	30 (27-34)	29 (26-32)	31 (27-35)	29 (24-37)	NS
LVMi (g/m²)	76.4 (61.6-100.4)	74.2 (66.2-97.8)	87.8 (72.9-100.3)	94.5 (70.8-117.1)	0.024*
Systolic function
Ejection fraction (%)	65 (60-70)	68 (63-72)	67 (61-71)	69 (63-74)	0.029*
Smax (cm/s)	6.6 (5.8-7.7)	6.6 (5.8-7.7)	6.4 (5.6-7.2)	6.1 (5.3-7.0)	0.005*
Diastolic function
LA-Index (ml/m²)	28.6 (23.8-35.3)	31.2 (25.7-35.2)	29.9 (25.7-36.9)	33.4 (27.9-38.8)	0.023*
E (cm/s)	60 (50-75)	60 (50-70)	70 (50-80)	70 (60-80)	NS
A (cm/s)	70 (60-80)	70 (60-80)	80 (70-90)	80 (70-95)	< 0.001*
E/A ratio	0.9 (0.7-1.2)	0.9 (0.7-1.1)	0.8 (0.7-1.0)	0.8 (0.7-1.1)	NS
E'septal (cm/s)	6.9 (5.6-8.0)	6.0 (5.3-7.3)	6.3 (5.3-7.3)	5.6 (4.9-6.2)	< 0.001*
E'lateral (cm/s)	9.1 (7.1-10.7)	8.6 (7.0-10.2)	8.3 (7.0-10.2)	7.5 (6.3-8.9)	0.001*
Average E'	7.9 (6.8-9.3)	7.4 (6.3-8.5)	7.6 (6.2-8.3)	6.4 (5.5-7.5	< 0.001*
E/E'septal ratio	8.8 (7.5-11.4)	10.3 (8.3-12.5)	10.8 (8.3-13.0)	12.1 (9.8-15.8)	< 0.001*
E/E'average ratio	7.5 (6.5-9.8)	8.5 (7.1—10.5)	8.9 (7.1-11.5)	10.5 (8.4-13.1)	< 0.001*
Laboratory
NT-pro-BNP (pg/ml)	81.40 (45.1-137.3)	93.25 (43.70-211.6)	104.6 (52.8-179.7)	218.2 (100.35-516.15)	< 0.001*

• ^*
  statistically significant (p < 0.05). IVS: interventricular septum; PLW: posterior lateral wall; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end‑systolic diameter; EF: ejection fraction; LA: left atrial; E: early diastolic transmitral velocity; A: late diastolic transmitral velocity; E': early diastolic tissue Doppler velocity; NT‑proBNP: N-terminal fragment of the prohormone B-type natriuretic peptide; DF: diastolic function; LVDD: left ventricular diastolic dysfunction; NS: non‑significant, HFpEF, heart failure with preserved ejection fraction. The Mann-Whitney U-test was used to analyze differences between the medians of two groups and the Kruskal‑Wallis test to test the equality of medians among more than two distinct groups.

Discussion

We hypothesized that circulating Endostatin levels are altered in patients with ALVDD and HFpEF. Furthermore, elevated levels are associated with the presence and severity of diastolic function abnormalities. To verify the hypothesis we performed a clinical observational study including 301 patients, which were assigned based on their echocardiographic characteristics to three different groups. To our knowledge, this is the first published report linking increased circulating Endostatin levels to the presence and severity of diastolic function abnormalities and HFpEF in a well phenotyped cohort of patients with normal systolic function. In the present study, Endostatin showed a graded increase from controls over ALVDD to HFpEF. Furthermore, higher Endostatin levels were significantly associated with established markers of structural cardiac abnormalities including the LAVi and increased LV mass as well as functional abnormalities like E/E' ratio. Particularly, an increased LAVi without concomitant mitral valve disease reflects a chronic remodeling process typical for HFpEF.²⁵ Consistently, we found that elevated Endostatin levels were associated with elevated NT-proBNP levels, a well-recognized prognostic marker and indicator of elevated ventricular filling pressures among patients, independent from LVEF.²⁶

Endostatin, a 20-kDa proteolytic fragment from the C-terminal domain of collagen XVIII, was shown to have an inhibitory effect on tumor growth working as an antiangiogenic growth factor.²⁷ Endostatin plays a role in the local balance of angiogenesis and shows potent anti-angiogenic activity by inhibiting proliferation and migration of endothelial cells in addition to inducing endothelial cell apoptosis.²⁷ Endostatin is produced by the proteolytic cleavage of the C-terminal domain of collagen XVIII, a component of the extracellular matrix. The precise mechanism of conversion from collagen XVIII to Endostatin has not yet been fully elucidated.^28,29 Recent studies of patients with coronary artery disease (CAD) demonstrate that Endostatin protein levels correlate significantly with reduced angiogenesis and poorly developed cardiac collateral vasculature.^18,30

The results from our study fit well to the pathophysiological model used to explain the development of HFpEF. In general, HFpEF is a complex disease involving an interplay of various factors. There is the hypothesis that a failure of oxygen delivery to the cardiomycytes triggers a pro-angiogenic response in patients suffering from heart failure.^31-33 Nonetheless, angiogenic and antiangiogenic growth factors often co-exist in tissues with angiogenesis.³⁴ Thus, the status of endothelial cells and endothelial function is determined by a balance between these positive and negative factors on angiogenesis, and the balance may in inappropriate shifted towards antiangiogenic factors in patients with HF. It was shown that the role of microvascular dysfunction and microvascular inflammation is especial for patients with the diagnosis of HFpEF.^5,35,36 A new pathophysiologic model presented by Redfield et al.⁸ points from pro-inflammatory coexisting conditions to systemic endothelial inflammation and impaired oxygen delivery.⁸ Global ventricular performance is highly dependent on oxygen supply and thus myocardial perfusion, and an essential component of myocardial perfusion during ventricular hypertrophy is the myocyte-microvascular balance and the myocyte/capillary ratio. In cardiac autopsy specimens, it has recently been shown that microvascular rarefaction is a downstream phenomenon in HFpEF.³⁷ Furthermore, Kitzman et al.³⁸ has demonstrated that HFpEF patients display significant abnormalities in the skeletal muscle as well as an abnormal capillary-to-fiber ratio, probably building the basis for severe exercise intolerance in HFpEF patients.³⁸ In addition, Gouya et al.¹⁹ have shown in a relatively small HFrEF study population that high levels of serum Endostatin were associated with all-cause mortality and concluded that the effect of increased angiogenesis is HF may be blunted by an overspill of anti-angiogenic factors such as Endostatin.¹⁹ Thus, we hypothesize that similar pathophysiological concepts may be involved in patients with HFpEF, were a high proportion of patients has a coincidence of coronary artery disease and diabetes, both damaging the endothelial structure.³⁹ This was also true for our patient population as shown in table 1. Endostatin could be moderator of the microvascular effects seen in these patients.⁴⁰

Several limitations of this study must be acknowledged. The observational nature of the present study prohibits definitive determination of cause and effect relationships. Second, the present study was a single-center experience with a relatively small number of subjects. Third, longitudinal follow-up data were not available to test associations between the Endostatin serum levels and clinical outcomes. Moreover, we enrolled consecutive patients referred for elective coronary angiography and echocardiography, which may not represent a general population cohort without evidence or suspicious for cardiovascular diseases.

Further studies should include more patients from a broader population and capture longitudinal data including information about hospitalization and mortality.

Conclusion

In this exploratory hypothesis-generating study, we provide first evidence that Endostatin correlates with the presence and severity of diastolic dysfunction and HFpEF and may become a novel biomarker for the diagnosis and stratification of HFpEF. Increased Endostatin levels may reflect deterioration of diastolic function caused by adverse remodeling. Further prospective studies are needed to determine the causal relationship as well as the diagnostic and prognostic value of Endostatin in HFpEF and the potential role as a therapeutic target.

• Sources of Funding

  There were no external funding sources for this study.

• Study Association

  This study is not associated with any thesis or dissertation work.

References

• ¹
  Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics-2016 Update: a report from the American Heart Association. Circulation. 2016;133(4):e38-360. doi: 10.1161/CIR.0000000000000350
  » https://doi.org/10.1161/CIR.0000000000000350
• ²
  Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123-33. doi: 10.1016/j.jacc.2013.11.053
  » https://doi.org/10.1016/j.jacc.2013.11.053
• ³
  Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. 2012;126(4):501-6. doi: 10.1161/CIRCULATIONAHA.112.125435
  » https://doi.org/10.1161/CIRCULATIONAHA.112.125435
• ⁴
  Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation Heart failure. 2013;6(3):606-19. doi: 10.1161/HHF.0b013e318291329a
  » https://doi.org/10.1161/HHF.0b013e318291329a
• ⁵
  Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Archiv : Eur J Physiol. 2014;466(6):1037-53. doi: 10.1007/s00424-014-1480-8.
  » https://doi.org/10.1007/s00424-014-1480-8
• ⁶
  Chan MM, Lam CS. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail. 2013;15(6):604-13. doi: 0.1093/eurjhf/hft062
• ⁷
  Lee DS, Gona P, Albano I, Larson MG, Benjamin EJ, Levy D, et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail. 2011;4(1):36-43. doi: 10.1161/CIRCHEARTFAILURE.110.957480
  » https://doi.org/10.1161/CIRCHEARTFAILURE.110.957480
• ⁸
  Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(19):1868-77. doi: 10.1056/NEJMcp1511175
  » https://doi.org/10.1056/NEJMcp1511175
• ⁹
  Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2017; 376(9):897. doi: 10.1056/NEJMc1615918
  » https://doi.org/10.1056/NEJMc1615918
• ¹⁰
  Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehw128
  » https://doi.org/10.1093/eurheartj/ehw128
• ¹¹
  Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):1810-52. doi: 10.1161/CIR.0b013e31829e8807
  » https://doi.org/10.1161/CIR.0b013e31829e8807
• ¹²
  Garg A, Virmani D, Agrawal S, Agarwal C, Sharma A, Stefanini G, et al. Clinical application of biomarkers in heart failure with a preserved ejection fraction: a review. Cardiology. 2017;136(3):192-203. doi: 10.1159/000450573
  » https://doi.org/10.1159/000450573
• ¹³
  Januzzi JL Jr, Felker GM. Surfing the biomarker tsunami .JACC Heart Fail. 2013;1(3):213-5.doi: 10.1016/j.jchf.2013.03.007
  » https://doi.org/10.1016/j.jchf.2013.03.007
• ¹⁴
  Balion C, McKelvie R, Don-Wauchope AC, Santaguida PL, Oremus M, Keshavarz H, et al. B-type natriuretic peptide-guided therapy: a systematic review. Heart Fail Rev. 2014;19(4):553-64. doi: 10.1016/j.jchf.2013.03.007
  » https://doi.org/10.1016/j.jchf.2013.03.007
• ¹⁵
  2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2016;22(9):659-69. doi: 10.1016/j.cardfail.2016.07.001
  » https://doi.org/10.1016/j.cardfail.2016.07.001
• ¹⁶
  Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, et al. Predictive value of endostatin in chronic heart failure patients with poor kidney function. Cardiology. 2015;130(1):17-22. doi: 10.1159/000368220
  » https://doi.org/10.1159/000368220
• ¹⁷
  Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Gaggin HK, et al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J Cardiovasc Translat Res. 2014;7(2):250-61. doi: 10.1007/s12265-013-9522-8
  » https://doi.org/10.1007/s12265-013-9522-8
• ¹⁸
  Mitsuma W, Kodama M, Hanawa H, Ito M, Ramadan MM, Hirono S, et al. Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation. Am J Cardiol. 2007;99(4):494-8. doi: 10.1016/j.amjcard.2006.09.095
  » https://doi.org/10.1016/j.amjcard.2006.09.095
• ¹⁹
  Gouya G, Siller-Matula JM, Fritzer-Szekeres M, Neuhold S, Storka A, Neuhofer LM, et al. Association of endostatin with mortality in patients with chronic heart failure. Eur J Clin Invest. 2014;44(2):125-35. doi: 10.1111/eci12197
  » https://doi.org/10.1111/eci12197
• ²⁰
  Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539-50. doi: 10.1093/eurheartj/ehm037
  » https://doi.org/10.1093/eurheartj/ehm037
• ²¹
  Evangelista A, Flachskampf F, Lancellotti P, Badano L, Aguilar R, Monaghan M, et al. European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. Eur J Echocardiogr. 2008;9(4):438-48. doi: 10.1093/ejechocard/jen174
  » https://doi.org/10.1093/ejechocard/jen174
• ²²
  Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-63. doi: :10.1016/j.echo.2005.10.005
  » https://doi.org/10.1016/j.echo.2005.10.005
• ²³
  Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol. 2004;43(8):1399-404.doi: 10.1016/j.jacc.2003.10.062
  » https://doi.org/10.1016/j.jacc.2003.10.062
• ²⁴
  Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10(2):165-93.doi: 10.1093/ejechocard/jep007
  » https://doi.org/10.1093/ejechocard/jep007
• ²⁵
  Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J. Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. Circ Heart Fail. 2014;7(6):1042-9. doi: 10.1161/CIRCHEARTFAILURE.114.001276
  » https://doi.org/10.1161/CIRCHEARTFAILURE.114.001276
• ²⁶
  van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 201361(14):1498-506. doi: :10.1016/j.jacc.2012.12.044
  » https://doi.org/10.1016/j.jacc.2012.12.044
• ²⁷
  O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-85. PMID:9008168
• ²⁸
  Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol. 1998;153(2):611-26. doi: 10.1016/S0002-9440(10)65603-9
  » https://doi.org/10.1016/S0002-9440(10)65603-9
• ²⁹
  Saarela J, Ylikarppa R, Rehn M, Purmonen S, Pihlajaniemi T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol. 1998;16(6):319-28. PMID: :9503365
• ³⁰
  Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, et al. Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. J Am Coll Cardiol. 2004;43(8):1383-7. doi: 10.1016/j.jacc.2003.10.063
  » https://doi.org/10.1016/j.jacc.2003.10.063
• ³¹
  Ohtsuka T, Inoue K, Hara Y, Morioka N, Ohshima K, Suzuki J, et al. Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy. Eur J Heart Fail. 2005;7(4):689-95. doi: 10.1016/j.ejheart.2004.09.011
  » https://doi.org/10.1016/j.ejheart.2004.09.011
• ³²
  Patel JV, Abraheem A, Chackathayil J, Gunning M, Creamer J, Hughes EA, et al. Circulating biomarkers of angiogenesis as indicators of left ventricular systolic dysfunction amongst patients with coronary artery disease. J Intern Med. 2009;265(5):562-7. doi: 10.1111/j.1365-2796.2008.02057.x
  » https://doi.org/10.1111/j.1365-2796.2008.02057.x
• ³³
  Friehs I, Margossian RE, Moran AM, Cao-Danh H, Moses MA, del Nido PJ. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol. 2006;101(3):204-13. doi: 10.1007/s00395-005-0581-0
  » https://doi.org/10.1007/s00395-005-0581-0
• ³⁴
  Toyota E, Matsunaga T, Chilian WM. Myocardial angiogenesis. Mol Cell Biochem. 2004;264(1-2 ):35-44. : :PMID: 15544033
• ³⁵
  Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol. 2008;6(4):292-300. PMID: 18855717
• ³⁶
  Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115(8):2108-18. doi: 10.1172/JCI24682
  » https://doi.org/10.1172/JCI24682
• ³⁷
  Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550-9. doi: 10.1161/CIRCULATIONAHA.114.009625
  » https://doi.org/10.1161/CIRCULATIONAHA.114.009625
• ³⁸
  Kitzman DW, Nicklas B, Kraus WE, Lyles MF, Eggebeen J, Morgan TM, et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. American journal of physiology Heart Circ Physiol. 2014;306(9):H1364-70. doi: 10.1152/ajpheart.00004.2014
  » https://doi.org/10.1152/ajpheart.00004.2014
• ³⁹
  Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115(1):79-96. doi: 10.1161/CIRCRESAHA.115.302922.
  » https://doi.org/10.1161/CIRCRESAHA.115.302922.
• ⁴⁰
  Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C, et al. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem. 2010;116(2):63-72. doi: 10.3109/13813451003652997.
  » https://doi.org/10.3109/13813451003652997

Publication Dates

• Publication in this collection
  28 Sept 2017
• Date of issue
  Nov 2017

History

• Received
  06 Apr 2017
• Reviewed
  04 July 2017
• Accepted
  24 July 2017